Linked Life Data

9158948

Source:http://linkedlifedata.com/resource/pubmed/id/9158948

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1997-7-24
pubmed:abstractText
To examine augmentation of the resistance-inducing effect of tumour vaccines with IL-2, we have used the cytokine produced by genetically modified somatic cells, and a conventional experimental model of TRA-expressing, MC-induced murine fibrosarcoma transplanted in histocompatible mice. We have found that the effect of s.c. immunization with irradiated tumour vaccines can be substantially enhanced by IL-2 injected repeatedly at the site of vaccination. To investigate the kinetics of local and systemic immunocyte populations during the course of immunization with vaccine plus IL-2, some of the vaccinated mice were sacrificed and their regional LNC and spleen cells were used for phenotypic analysis. It has been found that local (s.c.) administration of the irradiated tumour vaccine plus IL-2 was accompanied by an early depletion of CD4+ and CD8+ cells in regional lymph nodes followed by subsequent rebound lymphocytosis. The local reaction was followed by a systemic response in the spleen characterized with an increase in TCR alpha beta + CD4+ lymphocytes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0015-5500
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
39-40
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Recombinant interleukin-2 acts as an adjuvant and helps to increase the efficacy of tumour vaccines.
pubmed:affiliation
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't